menu
    • menu

    Company profile for Newron Pharmaceuticals

    NEW Drugs in Dev: 7
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US World Meds holds the commercialization rights...
    Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US World Meds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Newron PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    89 Headquarters Plaza North - Suite 306 Morristown, NJ 07960
    Telephone
    Telephone
    +1 973 993 1873
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    https://www.linkedin.com/company/newron-pharmaceuticals-spa/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Newron announces agreement with the European Investment Bank
    Newron announces agreement with the European Investment Bank

    19 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-19/newron-announces-agreement-with-the-european-investment-bank-eib-to-extend-the-near-term-tranche-repayment-dates-of-its-2018-finance-contract

    PHARMIWEB
    19 Mar 2026
    Share Share
    Newron Announces Board Nominations at Upcoming AGM Meeting
    Newron Announces Board Nominations at Upcoming AGM Meeting

    18 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-18/newron-announces-nominations-to-its-board-of-directors-at-upcoming-annual-general-meeting

    PHARMIWEB
    18 Mar 2026
    Share Share
    Newron Secures Up To EUR 38 Million To Advance Phase 3 Evenamide
    Newron Secures Up To EUR 38 Million To Advance Phase 3 Evenamide

    16 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260216652190/en/Newron-Secures-Up-to-EUR-38-Million-to-Advance-Phase-III-Evenamide-Program

    BUSINESSWIRE
    16 Feb 2026
    Share Share
    Newron Highlights Evenamide's Benefits In Schizophrenia
    Newron Highlights Evenamide's Benefits In Schizophrenia

    03 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-03/newron-notes-publication-highlighting-clinically-meaningful-benefits-of-evenamide-as-an-adjunctive-treatment-in-schizophrenia

    PHARMIWEB
    03 Feb 2026
    Share Share
    Eisai's EA Pharma Starts Phase III Trial For Evenamide
    Eisai's EA Pharma Starts Phase III Trial For Evenamide

    07 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-07/ea-pharma-a-subsidiary-of-eisai-announces-the-initiation-of-its-phase-iii-clinical-trial-with-even

    PHARMIWEB
    07 Jan 2026
    Share Share
    Newron Boosts Evenamide IP With EU Patent On 'Crystalline Forms'
    Newron Boosts Evenamide IP With EU Patent On 'Crystalline Forms'

    06 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-06/newron-further-expands-intellectual-property-portfolio-for-evenamide-with-new-eu-composition-of-matter-patent-ep4615820-crystalline-forms-of-even

    PHARMIWEB
    06 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search